Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphatic endothelial transcriptional regulator lncRNA 1 (LETR1)
- Target
- LETR1
- Molecular classification
- Long non-coding RNA (lncRNA), intergenic lncRNA
01
Overview
Lymphatic endothelial transcriptional regulator lncRNA 1 (LETR1) is a long non-coding RNA specifically and robustly expressed in lymphatic endothelial cells. LETR1 operates primarily within the cell nucleus as a trans-acting lncRNA, serving as a scaffold for epigenetic regulators that fine-tune the transcription of genes essential for lymphatic endothelial growth and migration, including *KLF4* and *SEMA3C*. Identified under the systematic names LINC01197 and CTD-2536I1.1, LETR1 belongs to the intergenic lncRNA family, functioning as a critical regulator of vascular identity and homeostasis. LETR1 does not encode a protein nor serve as a receptor, but its cell-type specificity makes it a potential biomarker for LECs and a plausible candidate in vascular developmental diseases.
- Other names
- LINC01197CTD-2536I1.1long intergenic non-protein coding RNA 1197GC15M105180GC15M106404
02
Mechanism of action
Not applicable; LETR1 is not a protein target. Its function involves modulation of chromatin and transcriptional networks via epigenetic scaffolding.
03
Biological functions
Transcriptional regulation in lymphatic endothelial cells (LECs)Scaffold for epigenetic complexesModulating growth and migratory ability of LECs
04
Disease associations
Potential role in glioma susceptibilityPossible involvement in corneal dystrophy (Lisch epithelial)Lymphatic vascular development and related disease processesMay inhibit influenza A virus replication (reported role for LINC01197)
05
Safety considerations
None reported in the literature; as a noncoding RNA, it is not associated with pharmacological side effects. However, its manipulation could theoretically disrupt lymphatic vascular homeostasis in experimental or therapeutic contexts
06
Biomarkers
LETR1 is highly specific to lymphatic endothelial cells and may serve as a lineage or cell-type biomarker for LECs
Beyond the preview
Go deeper on Lymphatic endothelial transcriptional regulator lncRNA 1 (LETR1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lymphatic endothelial transcriptional regulator lncRNA 1 (LETR1).